Sensei Biotherapeutics (SNSE) Competitors $8.22 -0.43 (-4.91%) Closing price 03:59 PM EasternExtended Trading$8.44 +0.22 (+2.67%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNSE vs. SNYR, RANI, DYAI, ESLA, RNTX, PMN, BDRX, ITRM, KZR, and OKURShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Synergy CHC (SNYR), Rani Therapeutics (RANI), Dyadic International (DYAI), Estrella Immunopharma (ESLA), Rein Therapeutics (RNTX), Promis Neurosciences (PMN), Biodexa Pharmaceuticals (BDRX), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. Its Competitors Synergy CHC Rani Therapeutics Dyadic International Estrella Immunopharma Rein Therapeutics Promis Neurosciences Biodexa Pharmaceuticals Iterum Therapeutics Kezar Life Sciences OnKure Therapeutics Sensei Biotherapeutics (NASDAQ:SNSE) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Do insiders & institutionals have more ownership in SNSE or SNYR? 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by company insiders. Comparatively, 56.6% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is SNSE or SNYR more profitable? Synergy CHC's return on equity of -8.48% beat Sensei Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sensei BiotherapeuticsN/A -66.72% -57.10% Synergy CHC N/A -8.48%12.75% Do analysts prefer SNSE or SNYR? Sensei Biotherapeutics presently has a consensus target price of $55.00, indicating a potential upside of 568.69%. Synergy CHC has a consensus target price of $10.00, indicating a potential upside of 179.33%. Given Sensei Biotherapeutics' higher probable upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Synergy CHC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has stronger valuation and earnings, SNSE or SNYR? Synergy CHC has higher revenue and earnings than Sensei Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.36Synergy CHC$34.83M0.94$2.12MN/AN/A Does the media refer more to SNSE or SNYR? In the previous week, Synergy CHC had 23 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 27 mentions for Synergy CHC and 4 mentions for Sensei Biotherapeutics. Synergy CHC's average media sentiment score of 0.92 beat Sensei Biotherapeutics' score of 0.50 indicating that Synergy CHC is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synergy CHC 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySynergy CHC beats Sensei Biotherapeutics on 8 of the 11 factors compared between the two stocks. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.36M$3.02B$5.55B$9.46BDividend YieldN/A2.46%4.73%4.15%P/E Ratio-0.3617.8028.9623.99Price / SalesN/A187.05376.6879.74Price / CashN/A40.5624.4827.24Price / Book0.279.018.655.84Net Income-$30.16M-$54.52M$3.25B$265.35M7 Day Performance20.78%2.07%0.45%-1.00%1 Month Performance-9.37%17.29%8.27%6.09%1 Year Performance-32.58%14.95%30.29%23.81% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.7166 of 5 stars$8.23-4.9%$55.00+568.7%-33.5%$10.36MN/A-0.3640News CoverageEarnings ReportAnalyst ForecastGap DownSNYRSynergy CHC3.9902 of 5 stars$3.72-1.8%$10.00+168.8%+11,600.0%$34.85M$34.83M0.0040News CoveragePositive NewsRANIRani Therapeutics1.9127 of 5 stars$0.55+3.6%$7.33+1,231.2%-79.5%$33.63M$1.03M-0.56110Negative NewsShort Interest ↑DYAIDyadic International2.0776 of 5 stars$1.11+0.9%$6.00+440.5%-25.2%$33.10M$3.49M-5.557News CoverageUpcoming EarningsESLAEstrella Immunopharma2.3789 of 5 stars$0.92+1.1%$16.00+1,639.1%-42.9%$32.91MN/A-3.54N/ARNTXRein TherapeuticsN/A$1.41-3.4%N/AN/A$32.34MN/A-0.499Positive NewsPMNPromis Neurosciences2.036 of 5 stars$0.90-8.8%$4.33+381.4%-47.3%$32.25MN/A-18.005Upcoming EarningsShort Interest ↑BDRXBiodexa Pharmaceuticals0.0777 of 5 stars$0.88flatN/AN/A$32.16MN/A0.0020News CoverageAnalyst DowngradeShort Interest ↑ITRMIterum Therapeutics1.5993 of 5 stars$0.78-2.8%$9.00+1,053.8%-40.5%$32.10MN/A-0.7910News CoverageShort Interest ↑KZRKezar Life Sciences3.5141 of 5 stars$4.36+1.2%$39.50+806.0%-33.0%$31.49M$7M-0.4060Negative NewsUpcoming EarningsAnalyst DowngradeShort Interest ↑OKUROnKure Therapeutics2.8439 of 5 stars$2.28-1.3%$32.33+1,318.1%N/A$31.21MN/A-0.43N/APositive NewsUpcoming EarningsGap Up Related Companies and Tools Related Companies SNYR Alternatives RANI Alternatives DYAI Alternatives ESLA Alternatives RNTX Alternatives PMN Alternatives BDRX Alternatives ITRM Alternatives KZR Alternatives OKUR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNSE) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
